Lupin gets tentative USFDA approval for Pregabalin capsules
Drug-maker Lupin today said it has received tentative approval from the US health regulator to market Pregabalin capsules, used in the treatment of chronic pain as a result from an injury to the nervous system, in the American market.
July 07, 2011 / 22:59 IST
Drug-maker Lupin today said it has received tentative approval from the US health regulator to market Pregabalin capsules, used in the treatment of chronic pain as a result from an injury to the nervous system, in the American market.
The company's US arm, Lupin Pharmaceuticals Inc, has received tentative approval from the US Food and Drug Administration (USFDA) for its Pregabalin capsules in strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg, Lupin Ltd said in a statement.Also read: Lupin gets tentative US FDA nod for anti-epilepsy drugLupin's Pregabalin capsules are the AB-rated generic equivalent of CP Pharmaceuticals' Lyrica capsules, which are indicated for neuropathic pain associated with diabetic peripheral neuropathy, among other ailments.According to IMS Health sales data, Lyrica capsules had annual US sales of nearly USD 1.7 billion for the twelve months ending March, 2011.Shares of Lupin were being quoted at Rs 461.20 apiece in late afternoon trade on the Bombay Stock Exchange today, up 2.43% from their previous close. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
